内皮抑素对人脐静脉内皮细胞(HUVEC) 及体外微血管 模型的作用及其可能的机制

目的：探讨内皮抑素对人脐静脉内皮细胞（HUVEC）及体外微血管模型的作用及其可能的机制。方法：1．MTT法检测不同浓度（10～50μg／ml）内皮抑素作用72h和30μg／ml内皮抑素作用不同时间（24～72h）对HUVEC细胞的影响;2、电镜观察HUVEC细胞超微结构的变化;3．光镜下观察内皮抑素（30μg／ml）对体外人造血管模型的影响。结果：1．MTT检测显示,内皮抑素（20～50μg／ml）能抑制HUVEC细胞的增殖（P〈0．05,P〈0．01）,具有剂量-时间依赖性。2．电镜观察,HUVEC细胞内皮抑素作用组均出现凋亡改变。3．光镜观察,内皮抑素能抑制新生血管的形成,并能破坏新生的血管网。结论：内皮抑素能抑制人脐静脉血管内皮细胞HUVEC的增殖,并具有时间一剂量依赖性,机制可能为诱导细胞凋亡。提示,内皮抑素可能通过诱导HUVEC的凋亡抑制其增殖,并能破坏新生的血管。内皮抑素可能以此抑制机体肿瘤的生长与转移。     

洛伐他汀联用格列本脲可改善高糖诱导损伤的HUVEC 功能

目的:探讨洛伐他汀与格列本脲联合用药对高糖诱导损伤的人脐静脉血管内皮细胞(HUVEC)的功能的影响及其机制。方法:以体外培养至第三代的HUVEC为研究对象,分四为:1空白对照组;2高糖组(33 mmol/L);3高糖组(33 mmol/L)+洛伐他汀(2μmol/L)组;4高糖组(33 mmol/L)+洛伐他汀(2μmol/L)+格列本脲(0.2μmol/L)组。用transwell小室法检测HUVEC的迁移功能,用细胞流式仪检测HUVEC内氧自由基(O~(2-))以及一氧化氮(NO)的表达水平。结果:与对照组相比,高糖组HUVEC迁移功能明显受损(P0.01);洛伐他汀单独用药组及其与格列本脲的联合用药组均能改善高糖损伤的HUVEC的迁移功能(均为P0.01)。流式结果显示,与对照组相比,高糖组HUVEC内O~(2-)水平明显增加而NO表达水平明显降低(均为P0.01);两组给药组HUVEC内O~(2-)水平及NO表达水平相对于高糖组均有明显改善(均为P0.01)。结论:洛伐他汀单独用药及其与格列本脲的联合用药均能改善高糖损伤的HUVEC的迁移功能,可能与改善细胞内氧化应激水平有关。     

CTSB 对人脐静脉血管内皮细胞系增殖及凋亡的影响

目的:探索组织蛋白酶B(CTSB)对人脐静脉血管内皮细胞系(HUVEC)增殖及凋亡的影响。方法:采用细胞转染法得到慢病毒空载体转染HU-MOCK细胞及CTSB过表达的HU-CTSB细胞,与正常的HUVEC细胞进行比较。采用MTT法检测HUVEC增殖情况;流式细胞仪检测各组细胞凋亡情况;采用蛋白免疫印迹法检测Bal-2/Bax及Caspase家族(Caspase-3/9)的表达情况。结果:HU-CTSB组各时间点HUVEC的增殖率明显低于其他两组,且差异具有统计学意义(P0.05);HU-CTSB组的HUVEC早期凋亡率(右下象限)和晚期凋亡率(右上象限)显著高于HUVEC组和HU-MOCK组,且组间差异具有统计学意义(P0.05);HU-CTSB组的抑制凋亡蛋白Bcl-2表达量明显低于其他两组,且促凋亡蛋白Bax表达量显著高于其他两组,差异均具有统计学意义(P0.05);HU-CTSB组caspases-3和caspases-9的活化片段显著高于其他两组,差异均具有统计学意义(P0.05)。结论:CSTB通过激活Caspase-3/9信号通路来上调Bax,并下调Bal-2,显著抑制HUVEC的增殖,并促进其凋亡,进而影响心血管疾病的发展。。     

HAT抑制剂诱导内皮细胞凋亡并抑制体外成管

乙酰化(acetylation)修饰是具有重要生物学意义的蛋白质翻译后修饰方式,由相互拮抗的组蛋白乙酰转移酶(histone acetyltransferase,HAT)和组蛋白去乙酰化酶(histone deacetylase,HDAC)所催化。近期发现HDAC抑制剂可通过抑制内皮细胞增殖等方式调节血管新生(angiogenesis),但HAT抑制剂是否有相反效应尚不明确。本研究观察了HAT抑制剂Garcinol对体外培养的人脐静脉内皮细胞HUVEC增殖、凋亡、迁移及成管的影响。结果发现,Garcinol在2.5~20μmol/L的范围内可剂量依赖性减少HUVEC的活细胞数目。Garcinol处理对HUVEC的细胞周期无明显影响,但Hochest染色、TUNEL染色及流式细胞术均发现Garcinol处理可显著诱导HUVEC的凋亡。此外,Garcinol处理还可抑制HUVEC的迁移和体外成管。以上结果提示:HAT抑制剂可能通过诱导内皮细胞凋亡而抑制血管新生,这可能是其抗肿瘤效应的新机制。     

肝细胞生长因子抑制糖基化终产物诱导人脐静脉内皮细胞的凋亡作用

目的探讨肝细胞生长因子(HGF)抑制糖基化终产物(AGEs)诱导人脐静脉内皮细胞凋亡的作用及其相关分子机制。方法体外培养ECV-304人脐静脉内皮细胞,采用噻唑蓝(MTT)法测定HGF对AGEs作用后ECV-304细胞生长抑制率的影响;通过Hoechst33258荧光染色观察细胞形态学改变、流式细胞术测定AnnexinV-FITC/PI双染标记的细胞凋亡率,检测HGF对AGEs诱导ECV-304细胞凋亡的影响;Western印迹法检测Bax、Bcl-2蛋白的表达。结果HGF能明显降低AGEs对ECV-304细胞生长的抑制作用;AGE诱导培养的ECV-304细胞出现明显的凋亡形态学改变,在一定浓度范围内,ECV-304细胞凋亡率与AGEs的浓度和作用时间呈依赖关系,加入HGF处理后可显著降低不同时间的内皮细胞凋亡率;HGF作用ECV-304细胞后Bcl-2蛋白表达明显升高,而Bax蛋白表达无明显变化。结论AGEs能诱导内皮细胞凋亡,而HGF能部分抑制AGEs诱导的内皮细胞凋亡,其作用机制可能与上调Bcl-2蛋白的表达水平有关。     

葡萄球菌肠毒素B诱导脐静脉内皮细胞凋亡机制的探讨

目的探讨金黄色葡萄球菌(金葡菌)肠毒素B诱导脐静脉内皮细胞凋亡的机制。方法将不同浓度金葡菌肠毒素B感染脐静脉内皮细胞8 h后,用流式细胞术检测细胞凋亡率,同时用比色法检测TNF-α、caspase-3及caspase-8的产生量,并检测加入TNF-α抗体、caspase-3和caspase-8抑制剂后的细胞凋亡率。结果不同浓度肠毒素B作用脐静脉内皮细胞8 h后均可诱导细胞凋亡,且TNF-α、caspase-3和caspase-8的产生量均高于对照组(P0.01);而加入TNF-α抗体、caspase-3和caspase-8抑制剂后凋亡率明显降低。结论金葡菌肠毒素B可以诱导脐静脉内皮细胞凋亡,其凋亡机制可能是通过TNF-α介导的caspase-8及caspase-3激活的外源性死亡因子受体途径。     

脱氧胆酸钠对人脐静脉内皮细胞凋亡的影响

目的:探讨脱氧胆酸钠(SD)对体外培养的人脐静脉内皮细胞(HUVEC)凋亡的影响。方法:(1)以不同终浓度(0、0.015mg/mL、0.05 mg/mL、0.15 mg/mL、0.5 mg/mL、1.0 mg/mL)的脱氧胆酸钠分别作用于人脐静脉血管内皮细胞,使用CCK-8检测细胞活力、TUNEL荧光染色检测细胞凋亡;(2)以终浓度为0.15 mg/mL的SD作用于HUVEC4、8、12 h后用Western blot检测Caspase-3、7、9蛋白及PARP活化情况;(3)观察Caspase-3抑制剂Z-DEVD-FMK对0.15 mg/mL脱氧胆酸钠组的影响。结果:CCK8结果显示随SD浓度(0~1.0 mg/mL)及作用时间(0~12 h)增加,HUVEC活力降低,0.15 mg/mL时活力为80%,1.0 mg/mL时细胞活力仅不到10%;Tunel检测示随着SD浓度的增加HUVEC凋亡明显增多;Western Blot结果示SD作用于HUVEC后Caspase-3、7、9蛋白及PARP活化明显增加;Z-DEVD-FMK明显抑制了0.15 mg/mLSD引起的PARP活化。结论:脱氧胆酸钠(SD)通过启动Caspase级联反应介导了人脐静脉内皮细胞的凋亡。     

十五肽BPC-157对人脐静脉内皮细胞功能的影响

目的:观察十五肽BPC-157对人脐静脉内皮细胞株HUVEC增殖、周期、迁移及小管形成的影响。方法:用不同浓度(0、1、5、10、50、100μg/mL)的BPC-157作用于HUVEC细胞株,采用MTT法检测药物对内皮细胞增殖的影响,通过流式细胞仪观察细胞周期的变化,经细胞划痕和Transwell实验检测药物对内皮细胞迁移的影响,并且通过小管形成实验观察BPC-157对内皮细胞小管形成能力的影响。结果:HUVEC细胞株经BPC-157刺激48 h后,细胞增殖率和各时期细胞比例没有明显变化;而在刺激12 h时,BPC-157显著性促进细胞伤口愈合及穿膜细胞数的增加(P0.01);刺激8 h时,给药组细胞开始聚合,形成复杂的管状网络结构,特别是5μg/mL剂量组。结论:十五肽BPC-157对人脐静脉内皮细胞株HUVEC增殖及细胞周期的改变基本没有影响,但对内皮细胞的迁移及小管形成能力具有明显的促进作用。     

核因子-κB在HUVEC细胞凋亡信号通路中的作用

目的：探讨核因子-κB（NF-κB）在人脐静脉内皮细胞凋亡信号通路中的作用。方法：体外培养人脐静脉内皮细胞系（HUVEC）,实验分为正常对照组、AngⅡ组和Gliotoxin干预组。应用改良MTF法,观察0．01μmol／L、0．1μmol／L、μmol／L和10μmol／L4种浓度的AngⅡ在不同时间对HUVEC细胞活性的影响。应用DNA凝胶电泳和流式细胞术检测AngⅡ作用于细胞后引起细胞凋亡的情况。应用免疫细胞化学技术检测NF-κB p65的核移位,评价NF-KB活化情况。结果：10μmol／L AngⅡ作用于细胞24h时,细胞活性下降,DNA凝胶电泳和流式细胞结果提示细胞发生凋亡,凋亡细胞率明显高于正常对照组,差异具有统计学意义（P〈0．05）,0．1mg／L Gliotoxin可拮抗AngⅡ的细胞抑制活性作用;免疫细胞化学技术显示,HUVEC细胞经AugⅡ诱导后,NF-κB出现明显核移位现象,提示NF-κB发生活化;Gliotoxin明显抑制NF-κB活化,与AngⅡ组相比,差异有统计学意义（P〈0．05）。结论：①ArcⅡ可引起HU—VEC细胞发生凋亡;而NF-κB特异性抑制剂Ghotoxin能够拮抗AngⅡ对HUVEC细胞的作用;②NF-κB可能是AngⅡ调控HUVEC细胞生存／凋亡通路中的重要信号转导分子。     

瑞舒伐他汀对OX-LDL诱导的人脐静脉内皮细胞PPAR-γ表达的影响

目的:探讨经氧化低密度脂蛋白(OX-LDL)刺激后,人脐静脉内皮细胞(PPAR-γ)表达的变化,以及瑞舒伐他汀对动脉粥样硬化的影响。方法:将实验标本随机分为2组,分为(OX-LDL)刺激组、瑞舒伐他汀干预组。应用RT-PCR及Western blot技术,观察OX-LDL诱导的人脐静脉内皮细胞PPAR-γ表达情况及瑞舒伐他汀对人脐静脉内皮细胞PPAR-γ表达的影响。结果:1)OX-LDL以时间及浓度依赖的方式降低了人脐静脉内皮细胞PPAR-γ的表达;2)瑞舒伐他汀可以逆转OX-LDL对人脐静脉内细胞的影响并可能与甲羟戊酸有关。结论:OX-LDL可降低人脐静脉内皮细胞PPAR-γ的表达。瑞舒伐他汀可以抑制OX-LDL诱导人脐静脉内皮细胞PPAR-γ表达的增强,从而可能抑制了OX-LDL信号通路介导的与炎症有关的血管损伤,延缓动脉粥样硬化的进程。     

蝎毒多肽提取物的抗血管生成作用

用不同浓度的东亚钳蝎素的多肽提取物PESV(4～20μg／ml)作用于人脐静脉内皮细胞(HUVEC),观察HUVEC增殖活性和凋亡变化,增殖活性检测采用BrdU掺入的ELISA法,凋亡水平和凋亡相关基因Bcl-2和Bax表达的检测采用流式细胞术检测;用鸡胚尿囊膜(CAM)显示PESV对血管生成的抑制作用。结果显示,PESV抑制HUVEC的增殖,而对乳腺癌细胞MDA-MB-231的增殖无明显影响;PESV作用72h后,HUVEC凋亡相关基因Bcl-2表达降低,Bax表达增加,凋亡细胞比例增至10．5％,明显高于对照组;0．5mgPESV能明显抑制CAM新生血管的形成。因此,PESV具有良好的体外抗肿瘤血管生成活性,PESV作为一种肿瘤血管抑制剂的天然药物来源,其有效成分和药理作用有待进一步研究。     

原核表达Arresten蛋白抑制血管生成作用

目的:研究原核表达的Arresten蛋白纯化品对血管内皮细胞及血管生成的抑制作用。方法:MTT法检测Arresten蛋白对人脐静脉内皮细胞(HUVEC)增殖的影响;流式细胞仪分析Arresten蛋白作用下HUVEC凋亡的情况;细胞迁移实验观察Arresten蛋白对HUVEC迁移能力的影响;鸡胚绒毛尿囊膜(CAM)实验观察Arresten蛋白对新生血管的抑制情况。结果:原核表达的Arresten蛋白纯化品能特异性地抑制 HUVEC的增殖、迁移,诱导HUVEC的凋亡,并在一定范围内呈现出剂量—效应关系。Arresten蛋白能有效抑制鸡胚尿囊膜血管的生长(P<0.01)。结论:原核表达的Arresten蛋白纯化品对内皮细胞有特异的抑制作用,能有效抑制血管生成。     

Proteomes of umbilical vein and microvascular endothelial cells reflect distinct biological properties and influence immune recognition

Human umbilical vein endothelial cells (HUVEC) are widely used as a source of endothelial cells (EC). However, HUVEC characteristics cannot be extrapolated to other types of EC, particularly microvascular ECs. Our objective was to compare the proteomes of microvascular ECs and HUVEC. Proteomes of HUVEC and human microvascular pulmonary EC (HMVEC-P) and dermal EC (HMVEC-D) from healthy Caucasian donors were compared by 2D DIGE and MS. Fatty acid binding proteins 4 and 5 were among the 159 and 30 proteins spots found to have at least twofold change in expression between HUVEC and HMVEC-D and between HUVEC and HMVEC-P samples, respectively. Eight protein spots showed twofold changed expression between HMVEC-D and HMVEC-P samples. Ingenuity? analysis revealed that proteins differentially expressed between HUVEC and HMVEC-D samples interact with retinoic acid. In vitro tubulogenesis assays showed a differential effect of retinoic acid between HUVEC and HMVEC. Moreover, serum IgG from patients with a rare vascular disease, systemic sclerosis, showed distinct reactivity profiles in HUVEC and HMVEC-D protein extracts. The proteome profiles of HUVEC and microvascular EC differ noticeably, which reflects distinct biological properties and influence immune recognition.     

Molecular hydrogen inhibits lipopolysaccharide/interferon γ-induced nitric oxide production through modulation of signal transduction in macrophages

Adipose-derived stem cells (ASCs) have been successfully applied in treating bone defects both in animals and humans and promoted osteogenesis in vivo significantly. However, the mechanism of in vivo osteogenesis of ASCs was still little known, we hypothesized that this was mediated in part by interaction between implanted ASCs and local vein endothelial cells. In this study, human adipose-derived stem cells (hASCs) and human umbilical vein endothelial cells (HUVEC) were isolated and characterized. Cells were then either cultured alone or cocultured. Alkaline phosphatase (ALP) staining, quantitative measurement of ALP activity and Alizarin staining of hASCs cultured alone, HUVEC cultured alone and cells cocultured demonstrated that osteogenic differentiation of cocultured cells increased obviously. Osteocalcin (OC) expression of hASCs cocultured with HUVEC showed an obvious raise than hASCs cultured alone. HUVEC cultured alone showed BMP-2 secretion and increased with culturing time. Real-time PCR of the cocultured cells showed four osteogenic differentiation related genes raised with culturing time, while two adipogenic differentiation related genes showed a slightly decrease with culturing time. Results of our study with different culture models showed that in vitro osteogenesis of hASCs was enhanced by coculture with HUVEC which secreted BMP-2. This study not only provided us with an in vitro model of studying interaction between cells, but also helped us to understand the in vivo therapeutic mechanisms of ASCs.     

Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells.

Tyrosine phosphorylation of cytoskeletal proteins occurs during integrin-mediated cell adhesion to extracellular matrix proteins. We have investigated the role of tyrosine phosphorylation in the migration and initial spreading of human umbilical vein endothelial cells (HUVEC). Elevated phosphotyrosine concentrations were noted in the focal adhesions of HUVEC migrating into wounds. Anti-phosphotyrosine Western blots of extracts of wounded HUVEC monolayers demonstrated increased phosphorylation at 120-130 kDa when compared with extracts of intact monolayers. The pp125FAK immunoprecipitated from wounded monolayers exhibited increased kinase activity as compared to pp125FAK from intact monolayers. The time to wound closure in HUVEC monolayers was doubled by tyrphostin AG 213 treatment. The same concentration of AG 213 interfered with HUVEC focal adhesion and stress fiber formation. AG 213 inhibited adhesion-associated tyrosine phosphorylation of pp125FAK in HUVEC. Tyrphostins AG 213 and AG 808 inhibited pp125FAK activity in in vitro kinase assays. pp125FAK immunoprecipitates from HUVEC treated with both of these inhibitors also had kinase activity in vitro that was below levels seen in untreated HUVEC. These findings suggest that tyrosine phosphorylation of cytoskeletal proteins may be important in HUVEC spreading and migration and that pp125FAK may mediate phosphotyrosine formation during these processes.     

Optimizing Transfection of Primary Human Umbilical Vein Endothelial Cells Using Commercially Available Chemical Transfection Reagents

Primary cells, such as HUVEC, are notoriously difficult to transfect and are susceptible to the toxic effects of transfection reagents. A transfection reagent with a high transfection efficiency and low cytotoxicity was sought to retain sufficient viability of transfected HUVEC for subsequent assays. Nine chemical transfection reagents, currently commercially available, were compared for their ability to transfect HUVEC in vitro. A plasmid expressing the enhanced GFP (EGFP) was used for transfection, followed by flow cytometry of transfected HUVEC to determine the proportion of EGFP-expressing cells as a measure of transfection efficiency. Lipofectamine 2000 and Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) gave the highest transfection efficiencies of the reagents tested. Lipofectamine LTX was identified as the optimal transfection reagent as a result of its higher transfection efficiency at shorter periods of time following transfection when cytotoxicity was limited, allowing sufficient yield of transfected HUVEC for use in subsequent assays.     

Inhibition of angiogenesis in vitro and in ovo with an inhibitor of cellular protein kinases, MDL 27032.

Protein kinase C (PKC) was implicated as an important positive regulator of angio-genesis by studies showing that tumor promoting phorbol esters, which activate PKC, stimulate angiogenesis both in vitro and in vivo. Therefore, inhibitors of PKC might be expected to block angiogenesis. MDL 27032 [4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone], an inhibitor of cellular protein kinases, prevented capillary-like tube formation by human umbilical vein endothelial cells (HUVEC) on basement membrane preparations, an in vitro model for angiogenic activity. MDL 27032 had an IC50 = 50 microM, whereas MDL 27044, the 4-methyl analog of MDL 27032, was less effective (IC50 greater than 100 microM). This selectivity was reflected in the relative abilities of the two compounds to inhibit PKC and protein kinase A (PKA) activity prepared from HUVEC, and also to inhibit the basic fibroblast growth factor stimulated proliferation of HUVEC. MDL 27032 (0.3 microgram/egg) also significantly inhibited neovascularization in yolk sac membranes of developing chick embryos, whereas MDL 27044 added at concentrations up to 3 micrograms/egg was not inhibitory when compared with vehicle treated controls. Adhesion of HUVEC to individual extracellular matrix proteins, including laminin, fibronectin, and fibrinogen, but not to the mixture of matrix components or collagen type I and IV, was inhibited after treatment with MDL 27032. These studies suggest that MDL 27032, may have potential as an anti-angiogenic agent because it disrupts both formation of tube-like structures by HUVEC on Matrigel and normal neovascularization in ovo. This inhibition may in part be due to altered cellular interactions with the extracellular matrix.     

芒柄花黄素在体外对内皮细胞细胞周期的影响

目的观察芒柄花黄素在体外对人脐静脉内皮细胞（HUVEC）增殖及周期的影响。方法采用四甲基偶氮唑蓝（MTT）法检测不同芒柄花黄素对HUVEC增殖的影响,流式细胞术检测细胞周期,Western blot检测cyclin D1蛋白表达水平。结果芒柄花黄素呈剂量依赖性促进HUVEC增殖。且药物作用后,S期细胞比例增加,cyclin D1蛋白表达升高。结论芒柄花黄素对人脐静脉内皮细胞有明显的促进增殖作用,可通过上调cyclin D1蛋白表达增加S期细胞比率。     

Agglucetin, a tetrameric C-type lectin-like venom protein, regulates endothelial cell survival and promotes angiogenesis by activating integrin alphavbeta3 signaling

Agglucetin, a platelet glycoprotein (GP)Ib binding protein from Formosan Agkistrodon acutus (A. acutus) venom, could sustain human umbilical vein endothelial cell (HUVEC) proliferation and HUVEC adhering to immobilized agglucetin showed extensive spreading, which was strongly abrogated by integrin antagonists 7E3 and triflavin. Flow cytometric analyses confirmed the expression of GPIb complex on HUVEC is absent and fluorescein isothiocyanate (FITC)-agglucetin binds to HUVEC in a dose-dependent and saturable manner. Furthermore, native agglucetin specifically and dose-dependently inhibited the binding of FITC-23C6, an anti-αvβ3 monoclonal antibody (mAb), but not antibodies against α2 and α5, toward HUVEC and purified αvβ3 also bound to immobilized agglucetin-β in a dose-dependent manner. Moreover, agglucetin exhibited a pro-angiogenic effect in vitro, as well as the focal adhesion kinase (FAK)-associated signaling molecules responsible for HUVEC activation were initiated by agglucetin. In conclusion, agglucetin, acting as a survival factor, promotes endothelial adhesion and angiogenesis by triggering αvβ3 signaling through FAK/phosphatidylinositol 3-kinase (PI3K)/Akt pathway.